Advertisement

A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals

  • Caroline C. ØhrstrømEmail author
  • Dorte L. Hansen
  • Urd Lynge Kielgast
  • Bolette Hartmann
  • Jens Juul Holst
  • Dorte Worm
Brief Communication

Abstract

Post-bariatric hypoglycemia (PBH) can be a serious complication after Roux-en-Y gastric bypass (RYGB), and treatment with somatostatin analogs has been suggested. We investigated the acute effects of three different doses of pasireotide (75 μg, 150 μg, and 300 μg) on the postprandial glucose metabolism in five RYGB-operated individuals with PBH using a mixed meal test. All three doses prevented hypoglycemia but were associated with a notable increase in postprandial hyperglycemia. Moreover, all doses greatly diminished insulin, C-peptide, and glucagon-like peptide-1 responses. Considering its strong hyperglycemic potential, we suggest that pasireotide should be administered carefully in RYGB-operated individuals with PBH, and if necessary, a 75 μg dose seems sufficient to prevent hypoglycemia.

Keywords

Gastric bypass Hypoglycemia Hyperglycemia Pasireotide Somatostatin analogs 

Notes

Compliance with Ethical Standards

Conflict of Interest

J.J.H. has served on the advisory board at Novo Nordisk and performed consulting services for MSD. C.C.Ø, D.L.H., U.L.K., B.H., and D.W. declare that they have no conflict(s) of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Statement of Informed Consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Lee CJ, Brown TT, Schweitzer M, et al. The incidence and risk factors associated with developing symptoms of hypoglycemia after bariatric surgery. Surg Obes Relat Dis Off J Am Soc Bariatr Surg. 2018;14(6):797–802.CrossRefGoogle Scholar
  2. 2.
    Gasser M, Meier C, Herren S, et al. Is testing for postprandial hyperinsulinemic hypoglycemia after gastric bypass necessary? Clin Nutr Edinb Scotl. 2019;38(1):444–9.CrossRefGoogle Scholar
  3. 3.
    Hanaire H, Bertrand M, Guerci B, et al. High glycemic variability assessed by continuous glucose monitoring after surgical treatment of obesity by gastric bypass. Diabetes Technol Ther. 2011 Jun;13(6):625–30.CrossRefGoogle Scholar
  4. 4.
    Tharakan G, Behary P, Wewer Albrechtsen NJ, et al. Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass. Eur J Endocrinol. 2017 Dec;177(6):455–64.CrossRefGoogle Scholar
  5. 5.
    de Heide LJM, Laskewitz AJ, Apers JA. Treatment of severe postRYGB hyperinsulinemic hypoglycemia with pasireotide: a comparison with octreotide on insulin, glucagon, and GLP-1. Surg Obes Relat Dis Off J Am Soc Bariatr Surg. 2014;10(3):e31–3.CrossRefGoogle Scholar
  6. 6.
    Tack J, Aberle J, Arts J, et al. Safety and efficacy of pasireotide in dumping syndrome—results from a phase 2, multicentre study. Aliment Pharmacol Ther. 2018;47(12):1661–72.CrossRefGoogle Scholar
  7. 7.
    Arts J, Caenepeel P, Bisschops R, et al. Efficacy of the long-acting repeatable formulation of the somatostatin analogue octreotide in postoperative dumping. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2009;7(4):432–7.Google Scholar
  8. 8.
    Øhrstrøm CC, Worm D, Højager A, et al. Postprandial hypoglycaemia after Roux-en-Y gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide. Diabetes Obes Metab. 2019 Sep;21(9):2142–51.CrossRefGoogle Scholar
  9. 9.
    Golor G, Hu K, Ruffin M, et al. A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers. Drug Des Devel Ther. 2012;6:71–9.CrossRefGoogle Scholar
  10. 10.
    Shenouda M, Maldonado M, Wang Y, et al. An open-label dose-escalation study of once-daily and twice-daily pasireotide in healthy volunteers: safety, tolerability, and effects on glucose, insulin, and glucagon levels. Am J Ther. 2014;21(3):164–73.CrossRefGoogle Scholar
  11. 11.
    Ashrafian H, Bueter M, Ahmed K, et al. Metabolic surgery: an evolution through bariatric animal models. Obes Rev. 2010;11(12):907–20.CrossRefGoogle Scholar
  12. 12.
    Deloose E, Bisschops R, Holvoet L, et al. A pilot study of the effects of the somatostatin analog pasireotide in postoperative dumping syndrome. Neurogastroenterol Motil. 2014;26(6):803–9.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of MedicineZealand University HospitalKøgeDenmark
  2. 2.Clinical DepartmentSteno Diabetes CenterCopenhagenDenmark
  3. 3.Department of Biomedical Sciences and Novo Nordisk Foundation Center for Basic Metabolic ResearchUniversity of CopenhagenCopenhagenDenmark
  4. 4.Department of MedicineAmager HospitalAmagerDenmark

Personalised recommendations